Future of Drug Development in Multiple Myeloma: An IMS-FDA Joint Workshop
The outcomes for patients with multiple myeloma have improved with the introduction of new therapies and approaches to care. However, relapses are common and multiple myeloma remains a difficult disease to treat, so the need for new therapies remains. Recent trial results and developments in the field of multiple myeloma necessitate a discussion of the current paradigm to facilitate future drug development and improve patient outcomes.
On November 8-9, 2022, the IMS will host a joint workshop with the FDA, to provide a forum for open discussion among academia, industry and regulatory agencies about clinical drug development in multiple myeloma. This workshop will discuss trial design, patient population, and endpoints in the different multiple myeloma disease settings with an aim to advance the future of drug development. Ultimately, this meeting serves to engage stakeholders to discuss opportunities and challenges in designing trials applicable to the US patient population.